157 related articles for article (PubMed ID: 25564801)
1. Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease.
Lee YM; Kang B; Lee Y; Kim MJ; Choe YH
J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):737-43. PubMed ID: 25564801
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
[TBL] [Abstract][Full Text] [Related]
3. [The clinical and endoscopic efficacy of step-up and top-down infliximab therapy in Crohn's disease].
Xiao YL; Chen BL; He Y; Gao X; Huang MJ; Hu PJ; Chen MH
Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):100-3. PubMed ID: 22490808
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
Veres G; Szabó D; Várkonyi A; Tari B; Polgár M; B Kovács J; Horváth A; Tomsits E; Tokodi I; Bodánszky H; Dezsofi A; Szakos E; Vass N; Ruszinkó V; Kovács M; Müller KE; Arató A
Orv Hetil; 2010 Jan; 151(5):179-83. PubMed ID: 20083466
[TBL] [Abstract][Full Text] [Related]
5. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
7. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.
Church PC; Guan J; Walters TD; Frost K; Assa A; Muise AM; Griffiths AM
Inflamm Bowel Dis; 2014 Jul; 20(7):1177-86. PubMed ID: 24865777
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of infliximab in treatment of pediatric Crohn's disease in China].
Luo Y; Yu J; Zhao H; Peng K; Lou J; Ma M; Chen J
Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):688-92. PubMed ID: 25476432
[TBL] [Abstract][Full Text] [Related]
9. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
[TBL] [Abstract][Full Text] [Related]
12. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
13. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.
Ghaly S; Costello S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; Antoniades S; Headon B; Connor S; Lawrance IC; Sparrow M; Walsh AJ; Andrews JM;
Intern Med J; 2015 Feb; 45(2):170-7. PubMed ID: 25370691
[TBL] [Abstract][Full Text] [Related]
14. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab Therapy in Pediatric Crohn Disease: A 2-Year Follow-Up Comparing "Top-Down" and "Step-Up" Strategies.
Payen E; Neuraz A; Zenzeri L; Talbotec C; Abi Nader E; Chatenoud L; Chhun S; Goulet O; Ruemmele FM; Pigneur B
J Pediatr Gastroenterol Nutr; 2023 Feb; 76(2):166-173. PubMed ID: 36305799
[TBL] [Abstract][Full Text] [Related]
16. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
17. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
18. [Long-term outcome of infliximab therapy in pediatric Crohn disease].
Wanty C; Stephenne X; Sokal E; Smets F
Arch Pediatr; 2011 Aug; 18(8):863-9. PubMed ID: 21723101
[TBL] [Abstract][Full Text] [Related]
19. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
